Ultragenyx (RARE)
Healthcare
Biotechnology
24.90 $
-4.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Ultragenyx (RARE)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 96.0% of the shares are freely tradable; institutional investors hold 104.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
104.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
3.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
96.0%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
15.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
99Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 10.42 | 10,263,815 | +1.3 | 12/31/2025 |
| BlackRock Inc | 7.41 | 7,299,598 | +10.1 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 5.47 | 5,385,992 | +0.0 | 03/31/2026 |
| State Street Corp | 5.10 | 5,021,441 | +16.7 | 03/31/2026 |
| AQR Capital Management LLC | 4.65 | 4,578,024 | +236.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.25 | 4,189,831 | +0.0 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 3.70 | 3,648,795 | +21.6 | 03/31/2026 |
| Sands Capital Management, LLC | 3.26 | 3,214,533 | -7.8 | 03/31/2026 |
| Sofinnova Ventures | 3.19 | 3,145,888 | +3,676.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.49 | 3,439,894 | -0.6 | 05/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.